Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Technology and Equipment, Bioprocessing - Upstream & Downstream, Drug Discovery

Dimensions of Progress

From left to right: Frank Junker, CBO, and Jan Lichtenberg, CEO, both at InSphero

With the ability to promote levels of cell differentiation and tissue organization not achievable in 2D cell models, a new generation of 3D disease models and assay technologies are changing the industry’s approach to the study of human pathophysiology. These organotypic 3D human tissue models enable drug developers to simulate conditions of complex diseases in a well, a feat that could potentially help shorten development cycles and produce better lead and compound identification. But despite the clear benefits of 3D assay technology, some reluctance to move away from 2D models lingers-- and not without reason. Pharma has an established history with 2D culture and a plethora of comparative literature cites their use. Even though simplistic 2D cell cultures don’t mimic human biology or allow cells to interact the way they would in vivo, 3D technologies and disease models have perceived challenges.  At first glance, 3D assays seem more expensive than comparable 2D assays and high-volume spheroid model production for industrial scale testing isn’t easy. Moreover, 2D fans will cite another valid concern: 3D cell cultures don’t lend themselves to maintaining quality readouts over time and thus have the potential to introduce variability into experiments. 

Here we speak to Jan Lichtenberg, CEO and Co-founder, and Frank Junker, CBO, both at InSphero, a biotechnology company based in Switzerland that provides scalable 3D in vitro cell culture platforms for drug discovery and safety testing, about the benefits 3D cell culture and disease models are bringing to the industry, the current challenges associated with adoption of new technology, and what it will take to encourage hesitant companies to explore 3D solutions further.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Maryam Mahdi

Associate Editor

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register